IGI 10% (TAK-339)
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 183 patients (estimated)
- Sponsors
- Takeda Oncology
- Collaborators
- Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
- Tags
- Randomization
- Trial Type
- Treatment
- Last Update
- 4 days ago
- SparkCures ID
- 2158
- NCT Identifier
- NCT06980480
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.